Dyslipidemia – Atherosclerosis
Dyslipidemia is an abnormal amount of lipids (e.g. high LDL-cholesterol levels or triglycerides) in the blood. In 2009, dyslipidemia was reported to cause the highest prevalence in cardiovascular disorders in developed countries, often due to western diet and lifestyle.
Dyslipidemia and atherosclerosis are two of the most important risk factors for cardiovascular diseases which are a major cause of morbidity and a leading cause of mortality worldwide.
- Outstanding scientific expertise and consultancy
- Innovative in-house diet-induced animal models
- Gold-standard methods and innovative techniques (the ox-LDL proprietary technique) to measure reverse cholesterol transport (RCT)
- Customized research solutions to target your needs
Animal Experimental Models
Nutrional animal models
ApoE KO and LDL-receptor KO mouse models
Insulin Resistant and dyslipidemic hamster model
Hypercholesteromic hamster model
Genetic animal models
ApoE KO mouse or LDL-receptor KO mouse
A constitutive KO model for cardiovascular disease. The mouse develops high level of plasma cholesterol and spontaneous atherosclerotic lesions while fed a standard diet.
ApoB 100 mouse
A genetically modified mouse model that contains the human apoliprotein B transgene. The animal develops atherosclerosis on a high fat diet.
A genetically modified mouse model that contains the human CETP transgene. The animal presents very low levels of plasma HDL cholesterol.
A leptin-deficient mouse model to study diabetes, obesity and diabetic dyslipidemia.
Zucker Diabetic Fatty (ZDF) rat
A genetic rat model for the study of type 2 diabetes, hyperglycemia, insulin resistance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia and cardiovascular or renal complications.
Zucker fatty rat
A genetic rat model of obesity, insulin resistance and hypertension.
Technical Platform / Read-Outs
|In vivo screening and profiling|
|Macrophage-to-feces reverse cholesterol transport||Gold-standard method|
|ox-LDL reverse cholesterol transport||In-house innovative and validated technique|
|HDL / LDL-cholesterol turnover||Gold-standard method|
|Intestinal triglycerides/cholesterol absorption||In-house validated technique|
|Whole body FFA turnover||Gold-standard method|
|In vivo individual tissue FFA storage rate||Gold-standard method|
|VLDL-TG production test||In-house validated technique|
|Euglycemic hyperinsulinemic clamp||Gold-standard method|
|Hyperglycemic clamp||Gold-standard method|
|Biochemistry / Biomarkers, Cardiometabolic parameters and other services|
|Biochemistry / Biomarkers||Yes|
|Lipid tolerance test||Yes|
|FPLC lipoprotein profiling||Yes|
|Basic services||Body weight, Food intake, Lipid homeostasis, Blood collection and tissue harvesting|
|Non invasive imaging services|
|Preclinical nuclear imaging services||Benefit of unique imaging services with innovative translational tracers associated with gamma imager, nanoSPECT/CT, nanoPET/CT, ultrasound imaging devices|